Table S1. Changes in the prevalence of overall transmitted drug resistance between missing and non-missing values across each sociodemographic variable by stages of NFATP development, from 2004 to 2022.
| Variable |
2004–2007
( n =1,251) |
2008–2011
( n =8,794) |
2012–2015
( n =21,467) |
2016–2019
( n =21,391) |
2020–2022
( n =4,999) |
P * |
Total
( n =57,902) |
|||||||||||||||||
| N † | n § | %** | N | n | % | N | n | % | N | n | % | N | n | % | N | n | % | |||||||
| Abbreviation: ART=antiretroviral therapy; HIV=human immunodeficiency virus; NFATP=National Free Antiretroviral Treatment Program. * P values were calculated using Cochran-Armitage trend test. P values <0.05 is statistically significant. † Total number of individuals infected with HIV who have not yet received ART surveyed. § The number of drug resistance amongst ART-naïve individuals infected with HIV. ¶ Proportion of ART-naïve individuals infected with human immunodeficiency virus who showcase drug resistance. | ||||||||||||||||||||||||
| Total | Missing or not | 1,251 | 32 | 2.6 | 8,794 | 283 | 3.2 | 21,467 | 740 | 3.4 | 21,391 | 953 | 4.5 | 4,999 | 392 | 7.8 | <0.001 | 57,902 | 2,400 | 4.1 | ||||
| Age | Yes | 1,054 | 22 | 2.1 | 6,603 | 208 | 3.2 | 15,685 | 506 | 3.2 | 10,076 | 383 | 3.8 | 1,348 | 106 | 7.9 | <0.001 | 34,766 | 1,225 | 3.5 | ||||
| No | 197 | 10 | 5.1 | 2,191 | 75 | 3.4 | 5,782 | 234 | 4.0 | 11,315 | 570 | 5.0 | 3,651 | 286 | 7.8 | <0.001 | 23,136 | 1,175 | 5.1 | |||||
| Sex | Yes | 778 | 16 | 2.1 | 4,929 | 164 | 3.3 | 13,959 | 469 | 3.4 | 9,513 | 362 | 3.8 | 1,347 | 106 | 7.9 | <0.001 | 30,526 | 1,117 | 3.7 | ||||
| No | 473 | 16 | 3.4 | 3,865 | 119 | 3.1 | 7,508 | 271 | 3.6 | 11,878 | 591 | 5.0 | 3,652 | 286 | 7.8 | <0.001 | 27,376 | 1,283 | 4.7 | |||||
| Ethnicity | Yes | 146 | 32 | 4.1 | 1,116 | 242 | 6.1 | 6,446 | 576 | 4.2 | 8,361 | 404 | 3.9 | 1,472 | 106 | 7.7 | <0.001 | 17,541 | 1,360 | 4.5 | ||||
| No | 1,105 | 0 | 2.4 | 7,678 | 41 | 2.8 | 15,021 | 164 | 3.1 | 13,030 | 549 | 4.8 | 3,527 | 286 | 7.9 | <0.001 | 40,361 | 1,040 | 4.0 | |||||
| Education | Yes | 1,251 | 32 | 2.6 | 7,340 | 242 | 3.3 | 16,958 | 576 | 3.4 | 10,417 | 404 | 3.9 | 1,369 | 106 | 7.7 | <0.001 | 37,335 | 1,360 | 3.6 | ||||
| No | 0 | 0 | 1,454 | 41 | 2.8 | 4,509 | 164 | 3.6 | 10,974 | 549 | 5.0 | 3,630 | 286 | 7.9 | <0.001 | 20,567 | 1,040 | 5.1 | ||||||
| Marital status | Yes | 1,251 | 32 | 2.6 | 6,892 | 229 | 3.3 | 16,960 | 560 | 3.3 | 10,367 | 401 | 3.9 | 1,365 | 106 | 7.8 | <0.001 | 36,835 | 1,328 | 3.6 | ||||
| No | 0 | 0 | 1,902 | 54 | 2.8 | 4,507 | 180 | 4.0 | 11,024 | 552 | 5.0 | 3,634 | 286 | 7.9 | <0.001 | 21,067 | 1,072 | 5.1 | ||||||
| Risk groups | Yes | 754 | 16 | 2.1 | 4,525 | 147 | 3.2 | 14,014 | 455 | 3.2 | 9,733 | 377 | 3.9 | 1,507 | 134 | 8.9 | <0.001 | 30,533 | 1,129 | 3.7 | ||||
| No | 497 | 16 | 3.2 | 4,269 | 136 | 3.2 | 7,453 | 285 | 3.8 | 11,658 | 576 | 4.9 | 3,492 | 258 | 7.4 | <0.001 | 27,369 | 1,271 | 4.6 | |||||
| CD4 count | Yes | 1,001 | 19 | 1.9 | 7,122 | 221 | 3.1 | 17,035 | 553 | 3.2 | 12,764 | 517 | 4.1 | 1,769 | 123 | 7.0 | <0.001 | 39,691 | 1,433 | 3.6 | ||||
| No | 250 | 13 | 5.2 | 1,672 | 62 | 3.7 | 4,432 | 187 | 4.2 | 8,627 | 436 | 5.1 | 3,230 | 269 | 8.3 | <0.001 | 18,211 | 967 | 5.3 | |||||